This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Relay Therapeutics (RLAY), Cigna (CI) and Sotera Health (SHC)

Tipranks - Tipranks - Tue May 5, 6:52AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Relay Therapeutics (RLAY), Cigna (CI) and Sotera Health (SHC) with bullish sentiments.

Claim 55% Off TipRanks

Relay Therapeutics (RLAY)

In a report released today, Salveen Richter from Goldman Sachs maintained a Buy rating on Relay Therapeutics, with a price target of $22.00. The company’s shares closed last Friday at $12.72.

According to TipRanks.com, Richter is a 4-star analyst with an average return of 10.3% and a 44.6% success rate. Richter covers the Healthcare sector, focusing on stocks such as Rapport Therapeutics, Inc., Ultragenyx Pharmaceutical, and 4D Molecular Therapeutics. ;'>

Relay Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $20.78, implying a 62.3% upside from current levels. In a report issued on April 27, Bank of America Securities also maintained a Buy rating on the stock with a $21.00 price target.

See the top stocks recommended by analysts >>

Cigna (CI)

In a report released yesterday, Scott Fidel from Goldman Sachs reiterated a Buy rating on Cigna, with a price target of $340.00. The company’s shares closed last Friday at $282.90.

According to TipRanks.com, Fidel is a 4-star analyst with an average return of 8.3% and a 64.4% success rate. Fidel covers the Healthcare sector, focusing on stocks such as Alignment Healthcare, Molina Healthcare, and Universal Health. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cigna with a $340.87 average price target, implying a 17.9% upside from current levels. In a report issued on April 20, Jefferies also maintained a Buy rating on the stock with a $330.00 price target.

Sotera Health (SHC)

In a report released today, Jason Bednar from Piper Sandler maintained a Buy rating on Sotera Health, with a price target of $24.00. The company’s shares closed last Friday at $15.50.

According to TipRanks.com, Bednar has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -5.8% and a 36.8% success rate. Bednar covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Merit Medical Systems, and Solventum Corporation. ;'>

Currently, the analyst consensus on Sotera Health is a Strong Buy with an average price target of $21.80.

Read More on RLAY:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).